$ICHR

BARROS PHILIP RYAN SR. sold $81K of ICHR

BARROS PHILIP RYAN SR. (Chief Executive Officer) sold 1,314 shares of ICHOR HOLDINGS, LTD. (ICHR) at an average of $61.88 ($61.39–$62.67) across 2 trades on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BARROS PHILIP RYAN SR.
Published Aug 20, 2026, 9:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ICHR
Neutral
high confidence
Mentioned
$ICHR
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICHRNeutralLow
01

Why it matters

The disclosed sale is routine and pre-arranged, offering little new insight for traders.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing motives not evident.

Relevance 2/10Novelty 4/10Timing: filed 2026-08-20

Background

Form 4 filing reports insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ICHRNeutralHigh confidence
Context

CEO Barros Philip Ryan Sr. sold 1,314 shares for $81,306 via a 10b5-1 plan, reducing his stake to 161,562 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale amount is small relative to market cap and follows a pre-arranged plan, indicating no new negative information.

Market effects

None; insider sale does not affect the broader biotech sector.

No regional impact.

Minimal; limited to ICHOR shareholders.

Counterpoint

The sale could signal upcoming negative news not yet disclosed.

Key entities

  • Barros Philip Ryan Sr.

    Chief Executive Officer of ICHOR HOLDINGS, LTD.

  • ICHR

    Ichor Holdings, a biotech company listed on NASDAQ.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICHRHighAI 8/10

Ichor (ICHR) Q3 2026 Earnings Call Transcript

Ichor (ICHR) reported Q3 2026 earnings, highlighting strong execution and earnings growth despite supply chain constraints. The company increased gross margins to 16%, ahead of plan, and expects full-year revenue growth of roughly 30%. Ichor is expanding manufacturing capacity and increasing proprietary content to support future demand and improve margins.

$ICHRMed

What Ichor (ICHR) Said on Its Q3 Earnings Call

Ichor (ICHR) reported Q3 earnings, noting supply constraints in high-end applications but improved revenue linearity. Q4 revenue is forecasted at $345M-$365M, with 8% sequential growth at the midpoint. Gross margin is expected at 16.5%±0.5%, and EPS at $0.65-$0.75. The company is investing in capacity expansion to support $3B revenue by 2027, with increased hiring and customer inventory backstopping.

$ICHRHighAI 9/10

Why is Ichor Holdings stock gaining today?

Ichor Holdings (ICHR) stock rose 0.2% after reporting Q3 2026 earnings of $0.63 per share, beating estimates by $0.18. Revenue grew 37% YoY to $328.7M, slightly missing expectations. The company guided Q4 EPS to $0.65-$0.75, well above consensus. Gross margin expanded to 16.0% from 5.1% YoY, but free cash flow turned negative.

$ICHRMed

Ichor Holdings, Ltd. Announces Third Quarter 2026 Financial Results

ICHOR HOLDINGS, LTD. (ICHR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ichor Holdings, Ltd. Announces Third Quarter 2026 Financial Results FREMONT, Calif., November 2, 2026–Ichor Holdings, Ltd. (NASDAQ: ICHR), a leader in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor ca